NasdaqGS - Nasdaq Real Time Price USD

BioMarin Pharmaceutical Inc. (BMRN)

81.03 -0.69 (-0.84%)
At close: May 10 at 4:00 PM EDT
81.03 0.00 (0.00%)
After hours: May 10 at 4:36 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
2,471,644.00
2,419,226.00
2,096,039.00
1,846,275.00
1,860,455.00
Cost of Revenue
504,562.00
514,854.00
483,669.00
470,515.00
524,272.00
Gross Profit
1,967,082.00
1,904,372.00
1,612,370.00
1,375,760.00
1,336,183.00
Operating Expense
1,792,925.00
1,746,273.00
1,566,406.00
1,450,093.00
1,428,016.00
Operating Income
174,157.00
158,099.00
45,964.00
-74,333.00
-91,833.00
Net Non Operating Interest Income Expense
48,582.00
41,004.00
2,064.00
-4,855.00
-12,699.00
Other Income Expense
14,616.00
-10,538.00
101,550.00
3,846.00
55,462.00
Pretax Income
237,353.00
188,563.00
149,576.00
-75,350.00
-48,997.00
Tax Provision
31,898.00
20,918.00
8,015.00
-11,270.00
-903,026.00
Net Income Common Stockholders
205,455.00
167,645.00
141,561.00
-64,080.00
854,029.00
Average Dilution Earnings
--
--
--
--
8,313.00
Diluted NI Available to Com Stockholders
207,287.00
167,645.00
141,561.00
-64,080.00
862,342.00
Basic EPS
1.09
0.89
0.76
-0.35
4.75
Diluted EPS
1.06
0.87
0.75
-0.35
4.53
Basic Average Shares
188,383.75
187,834.00
185,266.00
182,852.00
180,804.00
Diluted Average Shares
192,819.75
191,595.00
188,963.00
182,852.00
191,678.00
Total Operating Income as Reported
184,155.00
158,097.00
149,562.00
-82,341.00
-43,440.00
Total Expenses
2,297,487.00
2,261,127.00
2,050,075.00
1,920,608.00
1,952,288.00
Net Income from Continuing & Discontinued Operation
205,455.00
167,645.00
141,561.00
-64,080.00
854,029.00
Normalized Income
196,798.91
167,645.00
43,512.39
-57,276.55
818,755.40
Interest Income
65,761.00
58,339.00
18,034.00
10,482.00
16,610.00
Interest Expense
16,585.00
16,741.00
15,377.00
14,744.00
27,480.00
Net Interest Income
48,582.00
41,004.00
2,064.00
-4,855.00
-12,699.00
EBIT
253,938.00
205,304.00
164,953.00
-60,606.00
-21,517.00
EBITDA
359,253.00
309,690.00
266,922.00
47,433.00
83,655.00
Reconciled Cost of Revenue
460,075.00
472,668.00
444,500.00
424,376.00
481,300.00
Reconciled Depreciation
105,315.00
104,386.00
101,969.00
108,039.00
105,172.00
Net Income from Continuing Operation Net Minority Interest
205,455.00
167,645.00
141,561.00
-64,080.00
854,029.00
Total Unusual Items Excluding Goodwill
10,000.00
--
103,600.00
-8,000.00
48,320.00
Total Unusual Items
10,000.00
--
103,600.00
-8,000.00
48,320.00
Normalized EBITDA
349,253.00
309,690.00
163,322.00
55,433.00
35,335.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
1,343.91
--
5,551.39
-1,196.55
13,046.40
12/31/2020 - 7/26/1999

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ALNY Alnylam Pharmaceuticals, Inc.
150.47
-0.59%
 
INCY Incyte Corporation
53.06
-0.82%
 
HALO Halozyme Therapeutics, Inc.
43.15
-1.57%
 
SRPT Sarepta Therapeutics, Inc.
131.82
-0.36%
 
IONS Ionis Pharmaceuticals, Inc.
39.08
-0.99%
 
BBIO BridgeBio Pharma, Inc.
29.10
+1.29%
 
ARGX argenx SE
374.63
-2.07%
 
RARE Ultragenyx Pharmaceutical Inc.
40.90
-0.78%
 
BPMC Blueprint Medicines Corporation
106.70
-1.51%
 
AGIO Agios Pharmaceuticals, Inc.
33.00
+0.24%